Potent anti-inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo

Journal of Periodontal Research

Volumn 46, Issue 2, 2011, Pages 269-279

  Guimaraes M R ^a   Coimbra, L S ^a   De Aquino, S G ^a   Spolidorio, L C ^a   Kirkwood, K L ^b   Rossa, C ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Curcumin; Inflammation; Nuclear factor B; P38 mitogen activated protein kinase; Periodontal disease

Indexed keywords

COLLAGEN; CURCUMIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; ISOMERASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E SYNTHASE; PTGS2 PROTEIN, RAT; TUMOR NECROSIS FACTOR ALPHA;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; CELL COUNT; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; GINGIVA; IMAGE PROCESSING; INFLAMMATION; JAW; MALE; METHODOLOGY; MICRO-COMPUTED TOMOGRAPHY; PATHOLOGY; PERIODONTITIS; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT; THREE DIMENSIONAL IMAGING;

ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL COUNT; COLLAGEN; CURCUMIN; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GINGIVA; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; INFLAMMATION; INTERLEUKIN-6; INTRAMOLECULAR OXIDOREDUCTASES; MALE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERIODONTITIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 79951915925     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2010.01342.x     Document Type: Article

References (62)

1. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955-1968.
2. Sharma RA, Euden SA, Platton SL et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-6854.
3. Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 2000;131:169-172.
4. Kim HY, Park EJ, Joe EH, Jou I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 2003;171:6072-6079.
5. Duvoix A, Blasius R, Delhalle S et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005;223:181-190.
6. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995;55:259-266.
7. Anonymous. Clinical development plan: curcumin. J Cell Biochem Suppl 1996;26:72-85.
8. Swarnakar S, Ganguly K, Kundu P, Banerjee A, Maity P, Sharma AV. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem 2005;280:9409-9415.
9. Joe B, Rao UJ, Lokesh BR. Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol Cell Biochem 1997;169:125-134.
10. Kim GY, Kim KH, Lee SH et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 2005;174:8116-8124.
11. Gulcubuk A, Altunatmaz K, Sonmez K et al. Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med 2006;53:49-54.
12. Moon DO, Kim MO, Choi YH, Park YM, Kim GY. Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int Immunopharmacol 2010;10:605-610.
13. Mun SH, Kim HS, Kim JW et al. Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: inhibition of the PKCdelta/JNK/c-Jun pathway. J Pharmacol Sci 2009;111:13-21.
14. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-153.
15. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 2009;58:899-908.
16. Epstein J, Docena G, MacDonald TT, Sanderson IR. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 2010;103:824-832.
17. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009;15:2087-2094.
18. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005;50:2191-2193.
19. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007;43:294-315.
20. Graves DT, Oskoui M, Volejnikova S et al. Tumor necrosis factor modulates fibroblast apoptosis, PMN recruitment, and osteoclast formation in response to P. gingivalis infection. J Dent Res 2001;80:1875-1879.
21. Graves DT, Jiang Y, Valente AJ. The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Front Biosci 1999;4:D571-D580.
22. Jagetia GC, Rajanikant GK. Curcumin treatment enhances the repair and regeneration of wounds in mice exposed to hemibody gamma-irradiation. Plast Reconstr Surg 2005;115:515-528.
23. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-2087.
24. Sidhu GS, Singh AK, Thaloor D et al. Enhancement of wound healing by curcumin in animals. Wound Repair Regen 1998;6:167-177.
25. Garcia de Aquino S, Manzolli Leite FR, Stach-Machado DR, Francisco da Silva JA, Spolidorio LC, Rossa C Jr. Signaling pathways associated with the expression of inflammatory mediators activated during the course of two models of experimental periodontitis. Life Sci 2009;84:745-754.
26. Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409.
27. Lee HJ, Kang IK, Chung CP, Choi SM. The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. J Clin Periodontol 1995;22:885-890.
28. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol 1993;64:432-444.
29. Ejeil AL, Gaultier F, Igondjo-Tchen S et al. Are cytokines linked to collagen breakdown during periodontal disease progression? J Periodontol 2003;74:196-201.
30. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000;71:1535-1545.
31. Geivelis M, Turner DW, Pederson ED, Lamberts BL. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 1993;64:980-983.
32. Gorska R, Gregorek H, Kowalski J, Laskus-Perendyk A, Syczewska M, Madalinski K. Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J Clin Periodontol 2003;30:1046-1052.
33. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol 1991;62:504-509.
34. Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandol SJ. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. Am J Physiol 2003;284:G85-G95.
35. Plummer SM, Holloway KA, Manson MM et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999;18:6013-6020.
36. Gaddipati JP, Sundar SV, Calemine J, Seth P, Sidhu GS, Maheshwari RK. Differential regulation of cytokines and transcription factors in liver by curcumin following hemorrhage/resuscitation. Shock 2003;19:150-156.
37. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75:787-809.
38. Banerjee M, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003;25:213-224.
39. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991;57:1-7.
40. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471-480.
41. Polasa K, Sesikaran B, Krishna TP, Krishnaswamy K. Turmeric (Curcuma longa)-induced reduction in urinary mutagens. Food Chem Toxicol 1991;29:699-706.
42. Chen D, Nie M, Fan MW, Bian Z. Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis. Pharmacology 2008;82:264-269.
43. Balasubramanian S, Eckert RL. Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J Biol Chem 2007;282:6707-6715.
44. Suh HW, Kang S, Kwon KS. Curcumin attenuates glutamate-induced HT22 cell death by suppressing MAP kinase signaling. Mol Cell Biochem 2007;298:187-194.
45. Kim SJ, Hellerstein MK. Pharmacological doses of dietary curcumin increase colon epithelial cell proliferation in vivo in rats. Phytother Res 2007;21:995-998.
46. Cho JW, Park K, Kweon GR et al. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 2005;37:186-192.
47. Rossa C Jr, Liu M, Bronson P, Kirkwood KL. Transcriptional activation of MMP-13 by periodontal pathogenic LPS requires p38 MAP kinase. J Endotoxin Res 2007;13:85-93.
48. Sartori R, Li F, Kirkwood KL. MAP kinase phosphatase-1 protects against inflammatory bone loss. J Dent Res 2009;88:1125-1130.
49. Rossa C Jr., Liu M, Patil C, Kirkwood KL. MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts. Matrix Biol 2005;24:478-488.
50. Rossa C, Ehmann K, Liu M, Patil C, Kirkwood KL. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res 2006;26:719-729.
51. Patil C, Zhu X, Rossa C Jr., Kim YJ, Kirkwood KL. p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest 2004;33:213-233.
52. Patil C, Rossa C Jr, Kirkwood KL. Actinobacillus actinomycetemcomitans lipopolysaccharide induces interleukin-6 expression through multiple mitogen-activated protein kinase pathways in periodontal ligament fibroblasts. Oral Microbiol Immunol 2006;21:392-398.
53. Mbalaviele G, Anderson G, Jones A et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006;317:1044-1053.
54. Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res 2010;90:437-443.
55. Gopinath D, Ahmed MR, Gomathi K, Chitra K, Sehgal PK, Jayakumar R. Dermal wound healing processes with curcumin incorporated collagen films. Biomaterials 2004;25:1911-1917.
56. Guimaraes MR, Coimbra LS, de Aquino SG, Spolidorio LC, Kirkwood K L, Rossa C Jr. Curcumin modulates the immune response associated with LPS-induced periodontal disease in rats. Innate Immun 2011 (in press).
57. Liu L, Li C, Cai X, Xiang J, Cao Z, Dong W. The temporal expression and localization of extracellular matrix metalloproteinase inducer (EMMPRIN) during the development of periodontitis in an animal model. J Periodontal Res 2010;45:541-549.
58. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004;172:5940-5947.
59. Oh S, Kyung TW, Choi HS. Curcumin inhibits osteoclastogenesis by decreasing receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow stromal cells. Mol Cells 2008;26:486-489.
60. Hie M, Yamazaki M, Tsukamoto I. Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol 2009;621:1-9.
61. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995;206:533-540.
62. Miquel J, Bernd A, Sempere JM, Diaz-Alperi J, Ramirez A. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 2002;34:37-46.